Cancer combat promise bolstered by new Basel compound
In a significant breakthrough for cancer research, scientists at the University of Basel and the University Hospital Basel have developed a new balance molecule that could revolutionise immunotherapy treatments. This innovative compound, which combines an improved form of interleukin-2 (IL-2) with an antibody that blocks the braking effect of cancer cells, is currently being tested in a Phase I clinical trial.
Immunotherapy, a cancer treatment method that has been in use for 40 years, initially relied on IL-2. However, the initial therapy had its drawbacks, as it was able to activate the immune system but also strengthened cells that protect tumours from attack. The new balance molecule, on the other hand, overrides the "non-attack" signals sent by cancer cells to immune cells, primarily activating immune cells that eliminate abnormal cells, without activating cells that dampen the immune system.
The new balance molecule specifically incites immune cells in the tumour environment to attack. This targeted approach is a significant improvement over previous immunotherapy methods, which often activated the immune system indiscriminately, leading to severe side effects.
The study reporting the effectiveness of the new balance molecule was published in the prestigious journal "Science Translational Medicine" on Wednesday evening. The research involved laboratory experiments with cancer and immune cells from lung cancer patients. The results suggest that the new balance molecule could be a promising addition to the arsenal of cancer treatments.
Unfortunately, the study does not provide information about the leader of the research group at the University of Basel who allegedly developed the molecule that activates immunity against tumours. The current trial, being conducted in partnership with Roche and the University of Basel, will provide further insights into the efficacy and safety of this promising new treatment.
This advanced form of immunotherapy could potentially offer a more targeted and less harmful approach to cancer treatment, offering hope to patients and their families. As the trial progresses, we eagerly await further news and the potential for this groundbreaking treatment to become a reality.
Read also:
- Inadequate supply of accessible housing overlooks London's disabled community
- Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
- Duration of a Travelling Blood Clot: Time Scale Explained
- Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses
